BIOLASE (BIOL) Registration Filing summary

Company overview and business model

• Leading provider of advanced laser systems for dental practitioners, offering minimally invasive solutions for a wide range of dental procedures, including cosmetic, restorative, and surgical applications.

• Product portfolio includes Waterlase (all-tissue) and diode (soft-tissue) laser systems, with significant global patent coverage and FDA clearance for over 80 clinical indications.

• Revenue streams are split between laser system sales (51%) and consumables, accessories, and services (49%) as of Q1 2024.

• Over 47,700 laser systems sold in more than 80 countries since 1998.

Financial performance and metrics

• Net revenues were $10.1 million for Q1 2024, down slightly from $10.5 million in Q1 2023.

• Net loss attributable to common stockholders was $6.5 million for Q1 2024, compared to $5.8 million in Q1 2023.

• Total assets as of March 31, 2024, were $34.4 million, with a stockholders' deficit of $1.9 million.

• Accumulated deficit reached $323.3 million as of March 31, 2024.

• Cash and cash equivalents stood at $6.4 million as of March 31, 2024.

Use of proceeds and capital allocation

• Net proceeds from the offering are intended for working capital and general corporate purposes.

• Management has broad discretion over the use of proceeds, which may be temporarily invested in short-term, interest-bearing instruments.